Intellia Therapeutics, Inc. (NTLA) · Sep 8, 2026 · Other events

Intellia wins Priority Review for lonvo-z, setting March 2027 FDA decision

BLA accepted — Priority Review; PDUFA date March 10, 2027

FDA acceptance was expected, but Priority Review and no advisory panel sharpen the path toward a March 2027 decision for Intellia’s one-time HAE therapy.

The filing clears an expected regulatory milestone, but with better-than-standard review treatment. Intellia had already guided to FDA acceptance of the BLA in the second half of 2026 and a potential U.S. launch in the first half of 2027. The new information is that the FDA formally accepted the application, granted Priority Review, and set a March 10, 2027 PDUFA date. That makes this a partly known event rather than a complete surprise, but the accelerated review is a meaningful positive relative to the baseline timeline.

No planned advisory committee removes one visible regulatory hurdle. The FDA told Intellia it is not currently planning an advisory committee meeting. 〔0〕 This does not guarantee approval, but it reduces the risk of an additional public review step or a more complicated regulatory process before the PDUFA date.

The clinical package gives the filing substance, although the efficacy story was already known. HAELO showed an 87% reduction in mean monthly attacks versus placebo, while 62% of lonvo-z patients were attack-free and off HAE therapy during the six-month evaluation period versus 11% on placebo. 〔1〕 Those results support a credible approval case, but they are not new data in this filing and therefore do not represent an incremental earnings or clinical surprise.

Net read: modestly better than expected, with approval still the decisive event. The market already expected the BLA submission and a 2027 launch path; this filing upgrades the setup through Priority Review and the absence of a planned advisory committee, but it does not resolve the central approval risk. The next clean benchmark is the FDA’s March 10, 2027 action date.

What to watch next

FDA PDUFA decision, March 10, 2027

Original filing on SEC EDGAR

More Intellia Therapeutics, Inc. news

Intellia wins Priority Review for lonvo-z, setting March 2027 FDA decision | NTLA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.